<DOC>
	<DOCNO>NCT01196715</DOCNO>
	<brief_summary>REGIME compare two treatment , Darbepoetin Alpha ( DA ) Filgrastim ( Granulocyte Colony Stimulating Factor , G-CSF ) , standard treatment Myelodysplastic Syndrome ( MDS ) . After give Informed Consent patient undergo number test confirm eligibility . Once eligibility confirm patient randomly assign one three treatment group : A : Darbepoetin Alpha ( DA ) , B : Darbepoetin Alpha Filgrastim ( DA+G-CSF ) , C : Blood transfusion . Patients required attend clinic month 24 week . After 24 week patient react favorably treatment may continue treatment regime 52 week . After week 24 patient require attend clinic twice , week 36 52 . Patients follow 5 year record loss response , transformation Acute Myeloid Leukaemia and/or Refractory Anemia Excess Blasts death .</brief_summary>
	<brief_title>Comparison Study Standard Care Against Combination Growth Factors Agents Low-risk Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Males female age 18 year , ( upper age limit ) 2 . ECOG performance status 02 3 . Life expectancy 6 month 4 . A confirmed diagnosis MDS WHO type : refractory anaemia ( RA ) hypoplastic RA ineligible for/or fail immunosuppressive therapy ( ALG , cyclosporine ) refractory anaemia ring sideroblast ( RARS ) refractory cytopenia multilineage dysplasia myelodysplastic syndrome unclassifiable 5 . IPSS low Int1 , BM blast less 5 % 6 . A haemoglobin concentration le 10g/dl and/or red cell transfusion dependence 7 . Able understand implication participation Trial give write informed consent . 1 . MDS bone marrow blast great equal 5 % 2 . Myelodysplastic syndrome associate del ( 5q ) ( q3133 ) syndrome 3 . Chronic myelomonocytic leukaemia ( monocyte great than1.0x109/l ) 4 . Therapyrelated MDS 5 . Splenomegaly , spleen great equal 5 cm leave costal margin 6 . Platelets le 30x109/l 7 . Uncorrected haematinic deficiency . Patient deplete iron , B12 folate accord local lab range 8 . Women pregnant lactating . 9 . Females childbearing potential male must willing use effective method contraception ( hormonal barrier method birth control ; abstinence ) duration study 3 month last dose study medication . Note : Subjects consider child bear potential surgically sterile ( undergone hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal 10 . Females childbearing potential must negative pregnancy test prior start study . 11 . Uncontrolled hypertension , previous venous thromboembolism , uncontrolled cardiac pulmonary disease 12 . Previous serious adverse event study medication component 13 . Patients previous therapy ESAs Â± GCSF within 4 week study entry 14 . Patients currently receive experimental therapy , e.g . thalidomide , participate another CTIMP . 15 . Medical psychiatric illness , make patient unsuitable unable give inform consent . 16 . Patients malignancy require active treatment ( except hormonal therapy ) . 17 . Patients history seizure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Quality Life</keyword>
	<keyword>Erythroid response</keyword>
	<keyword>disease progression</keyword>
	<keyword>survival</keyword>
	<keyword>Overall erythroid response 24 week</keyword>
	<keyword>Quality life 24 week</keyword>
	<keyword>Quality life 12 , 36 52 week</keyword>
	<keyword>Overall erythroid response 12 52 week</keyword>
	<keyword>Incidence disease progression</keyword>
	<keyword>Overall Survival</keyword>
</DOC>